Bioxcel therapeutics announces promising top-line results from phase 2 trial of bxcl701 in aggressive form of rare prostate cancer

Results demonstrate encouraging response rate of bxcl701 plus keytruda® (pembrolizumab) in patients with scnc

BTAI Ratings Summary

BTAI Quant Ranking